Contribute Try STAT+ Today

In recent days, there’s been investor chatter about stalled-out Gilead Sciences (GILD) becoming a takeover target. The possibility that’s it’s vulnerable to acquisition even sparked a rally in its stock price last week — something the biotech’s own CEO, Dan O’Day, and his newly formed executive team couldn’t manage to do during their disappointing earnings call and 2020 outlook.

So I asked a health care investor what he made of all the talk. Was it legitimate or ridiculous?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Not so fast. I feel it (acquirer or acquiree) could depend a lot on the fate of the Remdesivir patent status both in China and globally. I have read and watched CGTV saying the Chinese Health Authorities hope Gilead would “donate” the patent or “agree to” a compulsory license.

Comments are closed.